Capricor's Burn Rate Soars Amid Zero Revenue, R&D Costs Double

TL;DR

**CAPR is burning cash at an alarming rate with no revenue, making it a high-stakes bet on Deramiocel's clinical success.**

AI Summary

CAPRICOR THERAPEUTICS, INC. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $74,873,032, a substantial rise from $33,350,583 in the same period of 2024. This was primarily driven by a sharp increase in operating expenses, with research and development costs surging to $61,321,924 from $35,413,649 year-over-year, and general and administrative expenses rising to $17,664,198 from $10,593,308. The company recorded no revenue for the nine months ended September 30, 2025, compared to $11,139,956 in the prior year, indicating a shift away from previous collaboration revenue. Despite the increased burn rate, cash and cash equivalents increased to $19,510,383 as of September 30, 2025, from $11,286,996 at December 31, 2024, largely due to proceeds from sales and maturities of marketable securities totaling $197,383,098. However, marketable securities decreased significantly to $79,055,588 from $140,228,881. The accumulated deficit grew to $274,707,571, up from $199,834,539 at December 31, 2024, reflecting ongoing losses. The company's liquidity, including cash, cash equivalents, and marketable securities, stood at approximately $98.6 million as of September 30, 2025.

Why It Matters

Capricor Therapeutics' substantial increase in net loss and zero revenue for the nine months ended September 30, 2025, signals a critical period for investors, highlighting the high-risk nature of clinical-stage biotechnology. The doubling of R&D expenses to over $61 million indicates aggressive investment in its Duchenne muscular dystrophy program, Deramiocel, which could lead to significant breakthroughs or further capital requirements. For employees, this aggressive spending suggests a focus on pipeline advancement but also underscores the pressure to deliver clinical success. Customers (future patients) are directly impacted by the pace and success of these R&D efforts. In a competitive landscape, Capricor's ability to secure additional financing and advance its lead candidate will determine its long-term viability and market position against larger pharmaceutical players.

Risk Assessment

Risk Level: high — The company reported a net loss of $74,873,032 for the nine months ended September 30, 2025, with zero revenue, compared to a net loss of $33,350,583 and $11,139,956 in revenue for the same period in 2024. Research and development expenses increased by over 73% to $61,321,924, indicating a significant cash burn without offsetting income. The accumulated deficit has grown to $274,707,571, demonstrating a history of substantial losses.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor upcoming clinical trial results for Deramiocel closely, as the company's financial health is entirely dependent on its pipeline success and ability to secure future funding. New investors should wait for clear positive clinical milestones or a more sustainable financial trajectory.

Financial Highlights

debt To Equity

0.51

revenue

$0

operating Margin

N/A

total Assets

$126.4M

total Debt

$42.6M

net Income

-$74.9M

eps

N/A

gross Margin

N/A

cash Position

$19.5M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $74.9M — Net Loss (Increased from $33.4M in 2024 for the nine months ended September 30, 2025)
• $0 — Revenue (Decreased from $11.1M in 2024 for the nine months ended September 30, 2025)
• $61.3M — Research and Development Expenses (Increased from $35.4M in 2024 for the nine months ended September 30, 2025)
• $17.7M — General and Administrative Expenses (Increased from $10.6M in 2024 for the nine months ended September 30, 2025)
• $274.7M — Accumulated Deficit (Increased from $199.8M at December 31, 2024)
• $98.6M — Cash, Cash Equivalents, and Marketable Securities (Total liquidity as of September 30, 2025)
• $19.5M — Cash and Cash Equivalents (Increased from $11.3M at December 31, 2024)
• $79.1M — Marketable Securities (Decreased from $140.2M at December 31, 2024)
• $197.4M — Proceeds from Sales/Maturities of Marketable Securities (Key source of cash for nine months ended September 30, 2025)
• 45,718,475 — Shares Outstanding (As of November 7, 2025)

Key Players & Entities

• CAPRICOR THERAPEUTICS, INC. (company) — clinical-stage biotechnology company
• Deramiocel (drug) — lead product candidate for Duchenne muscular dystrophy
• Duchenne muscular dystrophy (disease) — rare form of muscular dystrophy
• Nasdaq Capital Market (market) — exchange where CAPR is listed
• SEC (regulator) — Securities and Exchange Commission
• $74,873,032 (dollar_amount) — net loss for nine months ended September 30, 2025
• $61,321,924 (dollar_amount) — research and development expenses for nine months ended September 30, 2025
• $274,707,571 (dollar_amount) — accumulated deficit as of September 30, 2025
• $98.6 million (dollar_amount) — total liquidity (cash, cash equivalents, marketable securities) as of September 30, 2025
• September 30, 2025 (date) — end of reporting period

FAQ

Risk Factors

• Increasing Net Loss and Burn Rate [high — financial]: The company reported a net loss of $74,873,032 for the nine months ended September 30, 2025, a substantial increase from $33,350,583 in the prior year. This is driven by a significant rise in operating expenses, particularly R&D costs ($61.3M vs $35.4M) and G&A expenses ($17.7M vs $10.6M). This escalating burn rate, coupled with zero revenue, poses a significant financial risk.
• Decreasing Marketable Securities [medium — financial]: Marketable securities decreased from $140,228,881 as of December 31, 2024, to $79,055,588 as of September 30, 2025. While cash and cash equivalents increased to $19,510,383, the overall liquidity from these sources has declined, potentially impacting the company's ability to fund operations.
• Growing Accumulated Deficit [high — financial]: The accumulated deficit has grown to $274,707,571 as of September 30, 2025, up from $199,834,539 at the end of 2024. This indicates a long history of net losses and a substantial negative equity position, raising concerns about long-term financial sustainability.
• Dependence on Future Success of Pipeline [high — operational]: As a clinical-stage biotechnology company, Capricor's success is heavily dependent on the successful development and commercialization of its product candidates. Any setbacks in clinical trials, regulatory approvals, or market adoption could severely impact its financial condition and future prospects.
• Regulatory Approval Uncertainty [high — regulatory]: The company operates in a highly regulated industry. Obtaining approval from regulatory bodies like the FDA is a lengthy, expensive, and uncertain process. Delays or rejections in the approval process for its lead candidates would significantly hinder revenue generation and growth.
• Competition in the Biotechnology Sector [medium — market]: The biotechnology sector is highly competitive, with numerous companies developing therapies for similar indications. Capricor faces competition from established pharmaceutical companies and emerging biotechs, which could impact market share and pricing power.
• Need for Future Financing [high — financial]: Given the significant operating losses and increasing burn rate, Capricor will likely require substantial future financing to fund its ongoing research, development, and potential commercialization activities. The ability to secure such financing on favorable terms is not guaranteed.
• Reliance on Key Personnel [medium — operational]: The success of a biotechnology company often relies on the expertise of a small group of key scientific and management personnel. The loss of any of these individuals could disrupt research and development efforts and strategic direction.

Industry Context

Capricor Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cell and exosome-based therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on clinical trial outcomes, regulatory approvals, and the ability to secure substantial funding to advance pipeline candidates.

Regulatory Implications

As a clinical-stage biotechnology company, Capricor is subject to rigorous regulatory scrutiny from bodies like the FDA. The path to market approval for its therapies is complex and uncertain, with potential delays or rejections posing significant risks. Compliance with evolving regulations and successful navigation of the approval process are critical for future revenue generation.

What Investors Should Do

1. Monitor R&D spending closely: The significant increase in R&D expenses ($61.3M) needs to be evaluated against pipeline progress and clinical trial results to ensure efficient capital deployment.
2. Assess future financing needs: With a growing burn rate and zero revenue, investors should anticipate potential future equity or debt offerings and evaluate their dilutive impact.
3. Track clinical trial progress and regulatory milestones: The success of Capricor's lead product candidates is paramount. Investors should closely follow updates on clinical trial data and regulatory submissions.
4. Evaluate the sustainability of current cash reserves: While cash increased, the burn rate is high. Investors should assess how long current liquidity can sustain operations without additional funding.
5. Understand the shift in revenue: The complete absence of revenue in the nine months of 2025 compared to $11.1M in 2024 requires a clear understanding of the strategic reasons and future revenue generation plans.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any net profits. It represents the total loss that has not been offset by profits. (Indicates the company's historical unprofitability and the extent to which it has relied on external funding to cover its expenses.)

Marketable securities

Investments in financial instruments that can be easily bought or sold on public exchanges, such as stocks and bonds. (Represents a portion of the company's liquid assets that can be converted to cash, but their value can fluctuate.)

Research and development (R&D) expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. For a biotech company, this includes clinical trials, lab work, and personnel costs related to innovation. (A primary driver of expenses for a clinical-stage biotech company, reflecting investment in future growth and product pipeline.)

General and administrative (G&A) expenses

Costs associated with the overall management and operation of a business, including executive salaries, legal fees, accounting, and office expenses. (Represents the overhead costs of running the company, which have increased significantly.)

CIRM liability

Liability related to funding received from the California Institute for Regenerative Medicine (CIRM). This may involve repayment obligations or royalties. (Represents a specific financial obligation tied to a significant funding source, impacting the company's liabilities.)

Lease right-of-use assets

An asset recognized under accounting standards for leases, representing the lessee's right to use an underlying asset for the lease term. (Reflects the company's long-term commitments for leased assets, such as facilities or equipment, impacting both assets and liabilities.)

Deferred revenue

Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. It is recorded as a liability until earned. (Indicates payments received in advance for future services or products, which can provide a degree of future revenue certainty.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Capricor Therapeutics has experienced a dramatic shift. Revenue has fallen from $11.1 million to $0, while net loss has widened significantly from $33.4 million to $74.9 million. This is primarily due to a substantial increase in operating expenses, with R&D costs rising from $35.4 million to $61.3 million and G&A expenses increasing from $10.6 million to $17.7 million. While total assets have decreased, driven by a reduction in marketable securities, the company's cash position has improved due to the sale of securities, though the overall accumulated deficit has grown substantially.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M

Filing Documents

• capr-20250930x10q.htm (10-Q) — 1814KB
• capr-20250930xex31d1.htm (EX-31.1) — 10KB
• capr-20250930xex31d2.htm (EX-31.2) — 10KB
• capr-20250930xex32d1.htm (EX-32.1) — 6KB
• capr-20250930xex32d2.htm (EX-32.2) — 6KB
• 0001104659-25-109298.txt ( ) — 7108KB
• capr-20250930.xsd (EX-101.SCH) — 51KB
• capr-20250930_cal.xml (EX-101.CAL) — 46KB
• capr-20250930_def.xml (EX-101.DEF) — 195KB
• capr-20250930_lab.xml (EX-101.LAB) — 398KB
• capr-20250930_pre.xml (EX-101.PRE) — 323KB
• capr-20250930x10q_htm.xml (XML) — 1142KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 5 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 9 Notes to Unaudited Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 46

Controls and Procedures

Item 4. Controls and Procedures 47

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 48

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 48

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 48

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 48

Other Information

Item 5. Other Information 48

Exhibits

Item 6. Exhibits 49

Signatures

Signatures 50 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: how long we expect to maintain liquidity to fund our planned level of operations and our ability to obtain additional funds for our operations; the development of our drug and vaccine candidates, including when we expect to undertake, initiate and complete clinical trials of our drug and vaccine candidates; the expectation, plans, projections, initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials, compassionate uses, Investigational New Drug filings, Clinical Trial Application filings, New Drug Application filings, Biologics License Application, and other regulatory submissions; regulatory developments involving products and our facilities, including the timing and results of regulatory meetings and inspections, and the ability to obtain regulatory approvals or otherwise bring products to market in both the United States and in countries outside of the United States; the impact of any reductions in f

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS September 30, 2025 (unaudited) December 31, 2024 CURRENT ASSETS Cash and cash equivalents $ 19,510,383 $ 11,286,996 Marketable securities 79,055,588 140,228,881 Receivables 59,167 10,368,489 Prepaid expenses and other current assets 2,326,543 1,500,901 TOTAL CURRENT ASSETS 100,951,681 163,385,267 PROPERTY AND EQUIPMENT, net 11,068,078 5,561,597 OTHER ASSETS Lease right-of-use assets, net 13,929,710 1,312,522 Other assets 488,738 221,700 TOTAL ASSETS $ 126,438,207 $ 170,481,086 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 2,719,416 $ 3,283,712 Accrued expenses 9,932,488 4,907,665 Lease liabilities, current 120,094 834,799 CIRM liability, current 3,376,259 — Deferred revenue, current 12,000,000 12,000,000 TOTAL CURRENT LIABILITIES 28,148,257 21,026,176 LONG-TERM LIABILITIES CIRM liability, net of current — 3,376,259 Lease liabilities, net of current 14,422,695 616,315 TOTAL LONG-TERM LIABILITIES 14,422,695 3,992,574 TOTAL LIABILITIES 42,570,952 25,018,750 COMMITMENTS AND CONTINGENCIES (NOTE 6) STOCKHOLDERS' EQUITY Preferred stock, $ 0.001 par value, 5,000,000 shares authorized, none issued and outstanding — — Common stock, $ 0.001 par value, 100,000,000 shares authorized, 45,716,975 and 45,582,288 shares issued and outstanding , respectively 45,717 45,582 Additional paid-in capital 357,684,987 344,224,338 Accumulated other comprehensive income 844,122 1,026,955 Accumulated deficit ( 274,707,571 ) ( 199,834,539 ) TOTAL STOCKHOLDERS' EQUITY 83,867,255 145,462,336 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 126,438,207 $ 170,481,086 See accompanying notes to the unaudited condensed consolidated financial statements. 5 Table of Contents CAPRICOR THERAPEUTICS, INC. CONDENSED CONS

View Full Filing

View this 10-Q filing on SEC EDGAR